rese-cel (resecabtagene autoleucel)
Systemic Lupus Erythematosus (SLE)
Key Facts
About Cabaletta Bio
Cabaletta Bio's mission is to harness the immune system through innovative cell therapies to deliver accessible cures for autoimmune diseases. The company's core strategy leverages its proprietary CABA® platform, focusing on its lead CARTA candidate, rese-cel, which is designed to transiently eliminate B cells to 'reset' the immune system. It has rapidly advanced rese-cel into five concurrent Phase 1/2 RESET™ trials across lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris, positioning itself as a leader in applying CAR T technology to autoimmunity.
View full company profileAbout Cabaletta Bio
Cabaletta Bio's mission is to harness the immune system through innovative cell therapies to deliver accessible cures for autoimmune diseases. The company's core strategy leverages its proprietary CABA® platform, focusing on its lead CARTA candidate, rese-cel, which is designed to transiently eliminate B cells to 'reset' the immune system. It has rapidly advanced rese-cel into five concurrent Phase 1/2 RESET™ trials across lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris, positioning itself as a leader in applying CAR T technology to autoimmunity.
View full company profileAbout Cabaletta Bio
Cabaletta Bio's mission is to harness the immune system through innovative cell therapies to deliver accessible cures for autoimmune diseases. The company's core strategy leverages its proprietary CABA® platform, focusing on its lead CARTA candidate, rese-cel, which is designed to transiently eliminate B cells to 'reset' the immune system. It has rapidly advanced rese-cel into five concurrent Phase 1/2 RESET™ trials across lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris, positioning itself as a leader in applying CAR T technology to autoimmunity.
View full company profileAbout Cabaletta Bio
Cabaletta Bio's mission is to harness the immune system through innovative cell therapies to deliver accessible cures for autoimmune diseases. The company's core strategy leverages its proprietary CABA® platform, focusing on its lead CARTA candidate, rese-cel, which is designed to transiently eliminate B cells to 'reset' the immune system. It has rapidly advanced rese-cel into five concurrent Phase 1/2 RESET™ trials across lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris, positioning itself as a leader in applying CAR T technology to autoimmunity.
View full company profileAbout Cabaletta Bio
Cabaletta Bio's mission is to harness the immune system through innovative cell therapies to deliver accessible cures for autoimmune diseases. The company's core strategy leverages its proprietary CABA® platform, focusing on its lead CARTA candidate, rese-cel, which is designed to transiently eliminate B cells to 'reset' the immune system. It has rapidly advanced rese-cel into five concurrent Phase 1/2 RESET™ trials across lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris, positioning itself as a leader in applying CAR T technology to autoimmunity.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 2 |
| Nipocalimab | johnson-and-johnson-innovative-medicine | Phase 3 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| IFNα Kinoid (IFN-K) | Neovacs | Phase IIb |
| Brepocitinib (PF-06700841) | Priovant Therapeutics | Phase 3 |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| aiSLE® DX Disease Activity Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |
| RSLV-132 | Resolve Therapeutics | Phase 2 |
| Mini-CAR for SLE | Caravan Biologix | Pre-clinical |
| Internal Program | BenevolentAI | Preclinical |
| Telitacicept (RC18) | RemeGen | Approved |